These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
25. Your money or your life: a new variation on the Heinz Dilemma. Thompson RE Physician Exec; 2004; 30(1):58-61. PubMed ID: 14983708 [TBL] [Abstract][Full Text] [Related]
26. The real drug war. Beware, drug-makers. With senior citizens struggling to afford their prescriptions, soaring pill prices are turning into an explosive issue. Noonan D Newsweek; 2000 May; 135(19):28-31. PubMed ID: 10915520 [No Abstract] [Full Text] [Related]
27. US health spending up; Medicare expanded. Catton M CMAJ; 2005 Jun; 172(12):1545. PubMed ID: 15939907 [No Abstract] [Full Text] [Related]
28. Will reference pricing address the health cost conundrum? Iglehart JK Health Aff (Millwood); 2003; 22(3):7-8. PubMed ID: 12757267 [No Abstract] [Full Text] [Related]
29. Pharmaceutical industry pricing practices: impact of the Bayer settlement. Berkle M Health Care Law Mon; 2001 Jul; ():3-11. PubMed ID: 11484634 [No Abstract] [Full Text] [Related]
30. A first look at the new Medicare prescription drug plans. Frakt AB; Pizer SD Health Aff (Millwood); 2006; 25(4):W252-61. PubMed ID: 16720588 [TBL] [Abstract][Full Text] [Related]
31. The demise of the blockbuster? Cutler DM N Engl J Med; 2007 Mar; 356(13):1292-3. PubMed ID: 17392299 [No Abstract] [Full Text] [Related]
32. PBMs to the rescue? Pharmacy benefit managers will play a key role in the Medicare drug benefit. What does it mean for the industry, consumers and Uncle Sam? Fong T Mod Healthc; 2005 Nov; 35(48):26-8, 30. PubMed ID: 16617721 [No Abstract] [Full Text] [Related]
33. Fake pharmaceuticals: how they and relevant legislation or lack thereof contribute to consistently high and increasing drug prices. Moken MC Am J Law Med; 2003; 29(4):525-42. PubMed ID: 15119247 [No Abstract] [Full Text] [Related]
34. It's time to look at Rx pricing. Why study reimporting Canadian drugs when the real issue is U.S. prices? Sloane T Mod Healthc; 2004 Mar; 34(11):18. PubMed ID: 15069795 [No Abstract] [Full Text] [Related]
35. Increasing generic drug use in Medicare Part D: the role of government. Kohl H; Shrank WH J Am Geriatr Soc; 2007 Jul; 55(7):1106-9. PubMed ID: 17608887 [No Abstract] [Full Text] [Related]
36. Drug costs can be defended. Lee AM Med Mark Media; 1982 Mar; 17(3):36, 38, 40 passim. PubMed ID: 10309584 [No Abstract] [Full Text] [Related]
37. Should drug prices be negotiated under part D of Medicare? And if so, how? Frank RG; Newhouse JP Health Aff (Millwood); 2008; 27(1):33-43. PubMed ID: 18180478 [TBL] [Abstract][Full Text] [Related]
38. New Jersey leads the nation's quest for cures. N J Med; 1998 May; 95(5):30-3. PubMed ID: 16013154 [No Abstract] [Full Text] [Related]
39. Hypertension control: improved, but not enough! Alderman MH Am J Hypertens; 2007 Apr; 20(4):347. PubMed ID: 17386338 [No Abstract] [Full Text] [Related]
40. Are pharmaceuticals cost-effective? A review of the evidence. Neumann PJ; Sandberg EA; Bell CM; Stone PW; Chapman RH Health Aff (Millwood); 2000; 19(2):92-109. PubMed ID: 10718025 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]